Vermont
Novo Nordisk executive responds to criticisms of Ozempic cost, availability
Negelle Morris, Novo Nordisk's senior vice president and head of U.S. cardiometabolic sales, spoke exclusively with ABC News.
An executive for Novo Nordisk, the maker of popular drugs used for weight loss including Ozempic and Wegovy, says the company is investing over $6 billion dollars to help meet the increased demand fo… [+3275 chars]
Related
Share this page
Guest Posts by Easy Branches
